Atrial Fibrillation-Related Stroke across Latin America: A Preventable Problem

Working Group Recommendations

Dr. Carlos Cantú
National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico

Mellanie True Hills
StopAfib.org and the American Foundation for Women’s Health

Dr. Ayrton Massaro
Past-President of Ibero-American Stroke Society, Brazil

Professor Shinya Goto
Tokai University, Kanagawa, Japan

Professor Han-Hwa Hu
Taipei Veterans General Hospital, Taipei, Taiwan

Dr. David KL Quek
Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

Professor Dr. Kui-Hian Sim
Sarawak General Hospital, Sarawak, Malaysia

Professor Hung-Fat Tse
The University of Hong Kong, Hong Kong, China

Professor Shu Zhang
Fu Wai Cardiovascular Hospital, Beijing, China

Dr. Alastair Benbow
Fondation Universitaire, Brussels, Belgium

Professor Dr. Paulus Kirchhof
University of Birmingham, Birmingham, United Kingdom

Professor Dr. Karl-Heinz Ladwig
Technical University of Munich, Munich, Germany

Trudie Lobban MBE
Arrhythmia Alliance; AF Association

Dr. Xavier Viñolas
Hospital Sant Pau, Barcelona, Spain

This booklet was made possible by Bayer HealthCare Pharmaceuticals. See reverse of title page and acknowledgements for further information.

Disclaimer: this document is not intended for distribution to individual patients.
Atrial Fibrillation-Related Stroke across Latin America: A Preventable Problem

Working Group Recommendations

The recommendations in this document are endorsed by the organizations shown below.
Action for Stroke Prevention (ASP) has been initiated and funded by Bayer HealthCare as an independent alliance of experts with the aim to increase the awareness of atrial fibrillation and the associated risk of stroke. This booklet has been produced by ASP with the aid of financial support from Bayer HealthCare. Bayer HealthCare have also been given the opportunity to comment upon the booklet from a regulatory and compliance perspective. However, the content of this booklet has been determined, and full editorial control retained, by the authors independently of Bayer HealthCare in order to ensure the independence of the booklet and outputs of the group. The views expressed in this publication are not necessarily those of the sponsor.
Authors

**Writing group**

**Dr Carlos Cantú**
Chair, Department of Neurology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico; Professor of Stroke Program, National Autonomous University of Mexico, Mexico; Founding Member of the Mexican Stroke Association

**Mellanie True Hills**
Founder and Chief Executive Officer, StopAfib.org and the American Foundation for Women’s Health

**Dr Ayrton Massaro**
Past-President of Ibero-American Stroke Society; Co-chair of the 2012 World Stroke Conference, Brazil

**Professor Shinya Goto**
Professor of Medicine, Department of Medicine (Cardiology) and the Metabolic Disease Center, and the Department of Metabolic Systems Medicine, Institute of Medical Science, Tokai University, Kanagawa, Japan

**Professor Han-Hwa Hu**
Professor of Neurology, National Yang-Ming University, Taipei, Taiwan; Emeritus Chief of the Neurovascular Section, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; President of the Taiwan Stroke Association

**Dr David KL Quek**
Consultant Cardiologist, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; President of the Malaysia Medical Association and Elected Member of the Malaysian Medical Council

**Professor Dr Kui-Hian Sim**
Head of the Department of Cardiology and Head of Clinical Research Centre (CRC), Sarawak General Hospital, Sarawak, Malaysia; President of the National Heart Association of Malaysia

**Professor Hung-Fat Tse**
Professor of Medicine, Cardiology Division, Department of Medicine, The University of Hong Kong, Hong Kong, China

**Professor Shu Zhang**
Professor of Medicine, Chief of Department of Cardiology, Director of Arrhythmia Center; National Center for Cardiovascular Disease, Fu Wai Cardiovascular Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; President of Chinese Society of Pacing and Electrophysiology, Beijing, China

**Dr Alastair Benbow**
Executive Director, European Brain Council, (Brussels Office), Fondation Universitaire, Brussels, Belgium

**Professor Dr Paulus Kirchhof**
Chair in Cardiovascular Medicine, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom; Senior Consultant, Department of Cardiology and Angiology, University Hospital Münster; Germany

**Professor Dr Karl-Heinz Ladwig**
Professor of Psychosomatic Medicine and Psychological Medicine, Technical University of Munich; Deputy Director of the Chronic Disease Epidemiology Department of the Institute of Epidemiology at the Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany

**Trudie Lobban MBE**
Founder and Trustee, Arrhythmia Alliance; Founder and Chief Executive Officer, AF Association

**Dr Xavier Viñolas**
Director, Arrhythmia Unit, Hospital Sant Pau, Barcelona, Spain
Stroke in patients with atrial fibrillation in Latin America: a preventable problem

Working group

Dr Álvaro Avezum  
Director, Research Division, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil

Dr Jorge González-Zuelgaray  
Director of the Center of Cardiac Arrhythmias and of the Career of Specialists in Arrhythmias and Clinical Electrophysiology, University of Buenos Aires; Chief of Service of Arrhythmias and Electrophysiology (Sanatorio de la Trinidad San Isidro, Buenos Aires, Argentina); President of Arrhythmia Alliance and AF Association, Argentina

Dr Walter Reyes-Caorsi  
Chief, Electrophysiology Service, Casa de Galicia Hospital, Montevideo, Uruguay; Member, Continuing Medical Committee, Uruguayan Society of Cardiology; Member, Editorial Committee, Uruguayan Journal of Cardiology; Board Member, Honorary Commission for Cardiovascular Health; Director, Arrhythmia Council, South American Society of Cardiology

Professor Graeme J Hankey  
Head of Stroke Unit, Royal Perth Hospital, Perth, Western Australia; Clinical Professor, School of Medicine and Pharmacology, University of Western Australia, Nedlands, Australia

Professor Dayi Hu  
Chief of the Cardiology Division of Peking University’s People’s Hospital, Dean of the Medical College of Shanghai at Tongji University; Dean of the Cardiology Department of Capital University of Medical Science, Beijing, China; President of the Chinese Society of Cardiology; President of the Chinese College of Cardiovascular Physicians

Professor Norio Tanahashi  
Professor of Neurology, Saitama International Medical Center, Saitama Medical University, Hidaka City, Japan

Professor Byung-Woo Yoon  
Department of Neurology, Seoul National University Hospital; Director of Clinical Research Center for Stroke, Korea; Current President of the Korean Society of Stroke

Dr Felicita Andreotti  
Certified Professor, Department of Cardiovascular Sciences, Catholic University, Rome, Italy

Professor John Camm  
Professor of Clinical Cardiology, St George’s University, London, United Kingdom

Professor László Csiba  
Professor and Head of the Department of Neurology, University of Debrecen, Hungary; President of the European Society of Neurosonology and Cerebral Hemodynamics

Professor Antonio Dávalos  
Director, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Barcelona; Associated Professor of Neurology, Universitat Autònoma de Barcelona, Barcelona, Spain

Professor Dr Werner Hacke  
Professor and Chairman, Department of Neurology, University of Heidelberg, Heidelberg, Germany; Honorary President, European Stroke Organisation

Professor Michael G Hennerici  
Professor and Chairman of Neurology, Department of Neurology, University of Heidelberg, Universitätsklinikum Mannheim, Germany; Chairman, European Stroke Conference

Professor Richard Hobbs  
Professor and Head, Department of Primary Care Health Sciences, University of Oxford; National Director, NIHR School for Primary Care Research, United Kingdom; Chairman, European Primary Care Cardiovascular Society
Dr Torsten Hoppe-Tichy
Chief Pharmacist, Pharmacy Department, University Hospital of Heidelberg, Germany; President of ADKA (The German Society of Hospital Pharmacists)

Eve Knight
Chief Executive and Co-founder, AntiCoagulation Europe

Joe Korner
Director of Communications, The UK Stroke Association, London, United Kingdom; Representative for the Stroke Alliance For Europe (SAFE)

Professor Antoine Leenhardt
Professor of Cardiology, Paris 7 University; Head of the Arrhythmia Department, Bichat Hospital, Paris, France; Past-President of the French Working Group of Cardiac Arrhythmias and Pacing

Dr Maddalena Lettino
Chief of the Clinical Cardiology Unit, Istituto Clinico Humanitas, Rozzano (Milano), Italy; Past-Chair, Italian Atherosclerosis, Thrombosis and Vascular Biology (ATBV) Working Group; Chair of the Italian Working Group on Acute Cardiac Care; Board member of the ESC Acute Cardiovascular Care Association

Professor Lorenzo Mantovani
Professor, Faculty of Pharmacy, Federico II University of Naples, Naples, Italy

Rod Mitchell
Patient Advocate, Board Member, European Platform for Patients’ Organisations, Science and Industry (Eposi) and the European Genetics Alliance Network (EGAN); Past Board member, International Alliance of Patients’ Organizations

Professor Bo Norrving
Professor of Neurology, Department of Clinical Neurosciences, Section of Neurology, Lund University, Lund, Sweden; Past-President of the World Stroke Organization (2008–2012)

Professor Panos Vardas
President Elect of the European Society of Cardiology; Professor of Cardiology, University of Crete; Head of Cardiology Department, Heraklion University Hospital, Crete, Greece; President, European Heart Rhythm Association; Founder member of the Hellenic Cardiovascular Research Society and the Society’s first President

Acknowledgments
Support for the writing and editing of this booklet was provided by Chameleon Communications International Ltd, with funding from Bayer HealthCare. We acknowledge with thanks the contribution of Oxford PharmaGenesis™ Ltd who provided editorial and writing support for a previous report on the European Union: How Can We Avoid a Stroke Crisis? (2009), with funding from Bayer HealthCare.

The content of this booklet has been determined by the authors independently of Bayer HealthCare in order to ensure the independence of the booklet and outputs of the group.
Stroke in patients with atrial fibrillation in Latin America: a preventable problem
Endorsements

Academia Brasileira de Neurologia  www.sbdcv.com.br
Academia Nacional de Medicina  www.anm.org.uy/Inicio.php
ADKA – German Association of Hospital Pharmacists  www.adka.de
AntiCoagulation Europe (ACE)  www.anticoagulationeurope.org
Arrhythmia Alliance – International  www.aa-international.org
Arrhythmia Alliance – the Heart Rhythm Charity  www.arrhythmiaalliance.org.uk
Arrhythmia Alliance Argentina  www.aa-ar.org
Arrhythmia Alliance Brazil  www.aa-br.org
Arrhythmia Alliance Uruguay  www.aa-uy.org
AF Association – International  www.afa-international.org
AF Association – US  www.afa-us.org
AF Association Argentina  www.afa-ar.org
AF Association Brazil  www.afa-br.org
AF Association Chile  www.afa-cl.org
AF Association Colombia  www.afa-co.org
AF Association Ecuador  www.afa-ec.org
AF Association Mexico  www.afa-mx.org
AF Association Peru  www.afa-pe.org
Brazilian Society of Cardiology  www.escardio.org/EHRA
European Heart Rhythm Association  www.epccs.eu
European Primary Care Cardiovascular society  www.europostrooke.eu
European Stroke Conference  www.eso-stroke.org
European Stroke Organisation  www.interamericanheart.org
Federacion Argentina de Cardiologia  www.amevasc.org
InterAmerican Heart Foundation  www.pronetac.org.ar
Mexican Association of Cerebrovascular Diseases  www.safestroke.org
PRONETAC (Programa de Estudio y Tratamiento de las Arritmias Cardiacas)  www.stroke.org.uk
SAFE  www.stopafib.org
Stroke Association  www.ahfasf.org
StopAfib.org  www.fh-foundation.org
The International FH foundation  www.suc.org.uy
Uruguay Society for Cardiology (SUC)  www.sumi.org.uy
Uruguayan Society for Intensive Care Medicine  www.world-stroke.org
World Stroke Organization  www.world-stroke.org
Atrial fibrillation-related stroke: a global but preventable problem

◆ A stroke occurs when a blood vessel becomes blocked and the supply of blood to the brain becomes interrupted (ischemic stroke), or when blood from a ruptured vessel leaks into the brain (hemorrhagic stroke). Both can cause significant brain damage.

◆ Approximately 15% of all strokes are associated with atrial fibrillation (AF),\(^1\) an abnormal heart rhythm. The condition occurs with increasing frequency as people get older and is the most common heart rhythm disorder\(^2\).

◆ AF causes a stroke when the abnormal heart rhythm leads to the formation of a blood clot in the heart that is then transported to the brain. Patients with AF are five times more likely to experience a stroke than those without AF,\(^3\) and AF-related strokes are more severe than strokes unrelated to AF\(^4,5\).

◆ Stroke causes approximately 6 million deaths globally each year.\(^6\) In 2004, 437 000 people suffered a first-ever stroke in Latin America.\(^7\) The costs associated with stroke are considerable. Aggregate national healthcare expenditures of initial hospitalization for stroke in Brazil and Argentina alone have been calculated at US$449.3 million and US$434.1 million, respectively\(^8,9\).

◆ In this booklet, we look at key facts concerning the human and economic cost of this preventable type of stroke in Latin America, and how best to prevent it.

AF-related stroke is a major problem in Latin America today. However, it is a problem that can be overcome.

Atrial fibrillation-related stroke in Latin America: the avoidable burden

The clinical burden

◆ Although data regarding the prevalence of AF in Latin America are scarce, it is thought that there are a large number of people in the region living with the condition. In Brazil, an estimated 1.5 million patients are living with AF; in Venezuela, approximately 230 000 patients live with AF, with this figure predicted to rise to 1 million by 2050\(^10,11\).

◆ Stroke survivors often have permanent physical and cognitive disabilities; family members can also experience depression and a loss of independence\(^12–14\).

◆ AF is the most common sustained abnormal heart rhythm (arrhythmia) and occurs with increasing frequency as people get older\(^2\).

◆ In Latin America, the World Health Organization (WHO) estimated that the prevalence (i.e. total number of cases) of patients surviving a stroke in Latin America was 1.9 million in 2004.\(^15\) For that same year, the WHO estimated that 437 000 people suffered a first-ever stroke.\(^7\) The number of strokes per year is predicted to rise dramatically as the population ages, and it has been predicted that deaths resulting from ischemic heart disease and stroke in Latin America will almost triple by the year 2024\(^16,17\).

◆ Because of the larger size of the clot, AF-related stroke is more severe than non-AF-related stroke. It is associated with a higher risk of in-hospital death, greater disability, longer hospital stays, a reduced likelihood of patients returning to their own home, and increased risk of recurrent stroke\(^4,5\).

◆ As a result, AF-related stroke imposes a much greater burden on patients and their families than non-AF-related stroke.

The financial burden

◆ The financial burden placed on Latin American countries by stroke is huge. As noted above, national healthcare expenditures for initial hospitalization for stroke in Brazil and Argentina alone have been calculated at US$449.3 million and US$434.1 million, respectively\(^8,9\).

◆ Stroke costs are also higher in patients with AF compared with costs in patients without AF. Although mean cost data for cardioembolic stroke in patients in Latin American countries are scarce, cost data from Europe may offer an indication of the cost spread across the countries of the Latin American region.

• The mean costs of acute hospital care were shown to be higher for cardioembolic stroke (€4890 per patient; US$6948) than for non-cardioembolic stroke (€3550; US$5044) in a study of more than 500 patients in Germany\(^18\).

• Cardioembolic strokes are associated with a higher risk of recurrence than other types of stroke\(^19\).

◆ In addition, the financial burden of stroke in patients with AF is likely to be even greater for patients in Latin American countries where there is a high level of out-of-pocket expenditure on healthcare.\(^20\)
Improving stroke prevention: diagnosing atrial fibrillation earlier

◆ Although AF itself can be simple to diagnose, in many cases it goes undetected.

◆ One major problem with AF is that it is often asymptomatic. As a result, many patients are not diagnosed and do not receive the anticoagulation that they need.

◆ In recent years, strategies have been developed to improve detection of AF: a first step towards providing therapy for the prevention of AF-related stroke.

◆ Checking patients aged ≥65 years for an irregular pulse at their next visit and referring them for an electrocardiogram was an effective way of screening patients for AF in one UK-based primary care study.

◆ The Pan American Health Organization (PAHO) has proactively adapted the WHO’s STEPwise Method to Stroke Surveillance (STEPS Stroke) in Latin American countries as a useful tool to improve data collection, prevention, and treatment of stroke.

Preventing stroke in patients with atrial fibrillation: feasible and cost-effective, but underutilized

◆ For many years, oral anticoagulation with vitamin K antagonists (VKAs), such as warfarin, has been the ‘gold standard’ therapy for long-term stroke prevention in patients with moderate to high risk of stroke. In clinical studies, VKAs reduce stroke risk by an average of 64% compared with no therapy and by 38% versus aspirin.

◆ However, clinical trials are ‘controlled’ environments with strict trial conditions and careful anticoagulation monitoring. In real-life, VKAs are underused; several studies report anticoagulant use in <50% of patients with AF who are at high risk of stroke (Figure 1).

◆ Patients on VKAs may also spend much of their time (perhaps 45% on average) outside the ‘target’ therapeutic range for optimal therapy (referred to as the ‘international normalized ratio’ [INR] of 2.0–3.0). Based on these numbers, perhaps 25–30% of patients with AF receive optimal VKA therapy at any one time.

Figure 1. Patients with atrial fibrillation and prior stroke/transient ischemic attack: oral anticoagulation levels as a proportion of patients eligible for oral anticoagulation therapy.


◆ Contraindications taken into account.
Low time in therapeutic range (TTR) means that, for much of the time, a patient’s INR is either too low, increasing the risk of ischemic stroke, or too high, resulting in an increased risk of bleeding, especially intracranial hemorrhage (ICH). Because of this, low TTR (poor INR control) is associated with increased event rates and higher costs

Why is optimal prevention not achieved in practice?

- Successful VKA therapy requires frequent monitoring and dose adjustment to keep the patient within the INR range of 2.0–3.0. VKAs also have an unpredictable and variable dose-response and interact with many different foods, alcohol, and drug classes.

- Many physicians overestimate the risk of bleeding associated with VKAs and underestimate their benefits, particularly in elderly individuals. Patients themselves may also be unwilling to use them because of fears of side-effects.

- Physicians are often concerned about a patient’s ability to comply with VKA therapy because of the requirement for regular monitoring and dose adjustment, especially if the patient is elderly, lives alone, or has cognitive impairment.

- Regular INR monitoring may be especially difficult in some Latin American countries where some patients have limited access to healthcare resources, including INR monitoring facilities.

Suboptimal use of VKAs increases costs

- VKA therapy can be cost-effective for the prevention of AF-related stroke, even in elderly patients, however, this depends on how well it is managed.

- Data comparing the cost of AF-related stroke prevention using VKA therapy with the cost of treating stroke are not available for Latin American countries. However, data from the US highlight the cost reduction associated with optimal anticoagulation.

- The cost of stroke per patient with AF in those who were anticoagulated in routine medical care (approximately 70% of patients) was more than double that for patients attending specialized anticoagulation clinics (approximately 30% of patients) ($3710 vs $1485) in one US model (Figure 2). Much of this extra cost stemmed from managing complications associated with VKA therapy, such as bleeding. It is likely that further strokes resulting from underuse also increased costs.

Figure 2. Results of a 2004 economic model showing potential cost savings with optimal anticoagulation for stroke prevention in patients with atrial fibrillation in the US.
Cost of VKA monitoring

- Data on the cost of attending anticoagulation clinics in Latin American countries are not available. However, there are European studies that provide costs related to anticoagulation clinics.
  - The direct cost of routine INR monitoring has been estimated to be approximately €519 in the UK\textsuperscript{37} and €513 in Denmark,\textsuperscript{38} but can vary substantially depending on country and healthcare system.\textsuperscript{39} For example, considerably higher annual costs of approximately €1787 for the first year and approximately €980 for the second year have been estimated for Swedish primary care.\textsuperscript{40}
- Cost estimates often do not take into account the indirect costs incurred by the patient and their family (e.g. lost productivity and transport to clinic).
  - A questionnaire-based study of patients in the SPORTIF trial found that the average cost to patients of attending an anticoagulation clinic varied from €6.90 (France) to €20.50 (Portugal) per visit.\textsuperscript{41}
  - Over the course of many years, this can translate into substantial costs.

Recent advances in prevention of atrial fibrillation-related stroke:
non-vitamin K antagonist oral anticoagulants

- VKAs have their limitations, which contribute to their underuse.
- In recent years, the efficacy and safety of the non-VKA oral anticoagulants (OACs) rivaroxaban, dabigatran, and apixaban have been tested in large-scale global trials: ROCKET AF, RE-LY, and ARISTOTLE.\textsuperscript{42-44}
- These non-VKA OACs have distinct advantages over VKAs in that they:
  - Have predictable pharmacokinetics/pharmacodynamics. This means that, unlike the VKAs, a given dose of a non-VKA OAC always achieves the same degree of anticoagulation.
  - Have few food or drug interactions, in contrast to VKAs.
  - Are taken as fixed once-daily (rivaroxaban) or twice-daily (dabigatran) doses.
  - Require no routine coagulation monitoring.

- The ROCKET AF and RE-LY trials with rivaroxaban and dabigatran, respectively, have shown that these agents are at least as effective as VKAs for the prevention of AF-related stroke. They are also associated with significant reductions in ICH compared with VKA therapy – a particularly feared complication among physicians.\textsuperscript{42-44}
- Although the introduction of agents such as the non-VKA OACs are associated with increased drug costs relative to VKAs, the overall impact on the healthcare budget may be offset to some extent by the introduction of ‘generics’ for some key cardiovascular drugs. Furthermore, the improved safety profile of the non-VKA OACs can also be expected to further offset costs versus the VKAs.

What can be done: action steps

- Huge numbers of strokes that are attributable to AF occur each year in Latin American countries. The associated clinical, social, and human burdens are tremendous.
- The critical challenge is for key parties – healthcare professionals, policy-makers, industry, medical societies and patient advocacy groups alike – to work together to reduce the burden of AF-related stroke across Latin America.

Actions for policy-makers

- Raise public awareness and understanding of AF and the risk of AF-related stroke.
- Implement and support effective practice standards and targets for healthcare professionals; for example, standards for AF screening and availability of a choice of therapeutic options that meets patient needs.
- Implement national strategies for the early diagnosis of AF; these might include identifying patients who are at high risk of AF (owing to age, heart disease, alcohol consumption, high blood pressure or other chronic conditions), or promoting routine screening.
- Ensure equal and timely access to the best available care (such as anticoagulation clinics and newer therapies) for all patients with AF across Latin America, regardless of where they live or their background.
- Ensure that stroke prevention is addressed in national healthcare plans and that AF is recognized as a serious and significant risk factor for stroke.

\textsuperscript{a}Costs have been converted to Euros based on exchange rates at the time the study was carried out.
**Actions for medical societies and healthcare professionals**

◆ Maintain a good working knowledge of the most recent clinical guidelines and educate practising physicians to help ensure that patients with AF receive the best possible care available to them\(^45,46\)

◆ Inform colleagues in the healthcare profession of the importance of diagnostic checks for AF and of the benefit–risk of anticoagulation in patients with AF

◆ Ensure colleagues are aware of advances in development of new therapeutic options and of their potential benefits

◆ Ensure colleagues in the healthcare profession are trained on the appropriate use of approved non-VKA OACs

◆ Educate patients on why they are receiving treatment and the importance of taking their anticoagulation therapy as prescribed

◆ Ensure that healthcare payers understand the clinical and economic advantages of having access to new, alternative therapeutic options and how this will help to reduce the number of at-risk patients receiving sub-optimal treatment, through increased efficiency of treatment, thereby increasing prevention of AF-related stroke

**Actions for patient advocacy groups**

◆ Improve public awareness and understanding of AF and the risk of AF-related stroke. Campaigns such as the global ‘Know Your Pulse’ campaign and the ‘Sign Against Stroke in Atrial Fibrillation’ campaign both increase patient understanding and provide a collective means for patients to call on local policy-makers to improve care\(^47\)

◆ Help patients to understand the benefits and risks of different therapies and to make informed choices regarding their own therapy. In addition, help patients to understand why they always need to take their therapy according to the prescribed schedule

◆ Ensure healthcare payers not only consider robust clinical data but also listen to the patient voice to ensure their decisions reflect patient need

---

**AF-related stroke is a major burden that will continue to grow, and urgent action to tackle the problem is needed. However, the solution is in our hands – earlier diagnosis and better treatment will allow us to dramatically limit the impact of this devastating but preventable condition**
References


22. Fitzmaurice DA, Hobs FDR, Jovett S et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007;335:383


Conflicts of Interest

Dr Felicita Andreotti
Speaker/consultant: AstraZeneca, Bayer, BMS-Pfizer, Daiichi Sankyo, Eli Lilly

Dr Álvaro Avezum

Dr Alastair Benbow
The European Brain Council is a not for profit organisation which receives core funding from it’s members including scientific societies, patient groups and the pharmaceutical and device industries. It also receives specific project funding from EU institutions and industry

Professor John Camm
Advisor/speaker: AstraZeneca, ChanRX, Gilead, Merck, Menarini, Otsuka, Sanofi, Servier, Xention, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi, Pfizer, Boston Scientific, Biotronik, Medtronic, St. Jude Medical, Actelion, GlaxoSmithKline, InfoBionic, Incarda, Johnson & Johnson, Mitsubishi, Novartis, Takeda

Professor Shinya Goto
Research grants: Sanofi-Aventis, Otsuka, Boehringer Ingelheim, Daiichi Sankyo, Honoraria: Sanofi-Aventis, AstraZeneca., Eisai, Otsuka, Bayer, Novartis, Astellas, Pfizer, Medtronics-Japan, Tanabe-Mitsubishi, Takeda, Daiichi Sankyo, Mochida, MSD

Professor Dr Werner Hacke
Consultant: Boehringer Ingelheim, Bayer. Speaker: Boehringer Ingelheim, Bayer. Research support: Boehringer Ingelheim, unrestricted grant for ECASS 4 (an IIT)

Professor Graeme J Hankey
Honoraria: Executive Committees – AMADEUS (Sanofi-Aventis), ROCKET AF (Johnson & Johnson), BOREALIS (Sanofi-Aventis); Steering Committee – TRA 20P TIMI 50; Stroke Outcome Adjudication Committees – RE-LY, AVERROES. Speaker/Consultant: Bayer, Boehringer Ingelheim, Pfizer Australia

Professor Michael G Hennerici
None

Mellanie True Hills
None

Professor Richard Hobbs
Speaker fees/sponsorship: AstraZeneca, Bayer, Boehringer Ingelheim, Medtronic, Merck, Novartis, Pfizer, Roche

Dr Torsten Hoppe-Tichy
None

Professor Dayi Hu
None

Professor Han-Hwa Hu
None
**Professor Dr Paulus Kirchhof**  
Consulting fees/honoraria: 3M Medica, MEDA Pharma, AstraZeneca, Bayer Healthcare, Biosense Webster, Boehringer Ingelheim, Daiichi Sankyo, German Cardiac Society, MEDA Pharma, Medtronic, Merck, MSD, Otsuka Pharma, Pfizer/BMS, Sanofi, Servier, Siemens, TAKEDA. Research grants: 3M Medica/MEDA Pharma, Cardiovascular Therapeutics, Medtronic, OMRON, Sanofi, St. Jude Medical, German Federal Ministry for Education and Research (BMBF), Fondation Leducq, German Research Foundation (DFG), European Union (EU). Travel support: ESC, EHRA, AFNET

**Eve Knight**  
None

**Joe Korner**  
None

**Professor Dr Karl-Heinz Ladwig**  
None

**Professor Antoine Leenhardt**  
Board member/conference speaker: Sanofi, Bayer, Daiichi Sankyo, Boehringer Ingelheim, Meda Pharma, Pfizer, MSD, St. Jude Medical, Boston, Servier

**Dr Maddalena Lettino**  
Speaker: AstraZeneca, BMS, Boehringer, Eli Lilly, Daiichi Sankyo, Bayer, Pfizer, The Medicines Company. Advisory board member: Eli Lilly, The Medicines Company, BMS, Pfizer, MSD

**Professor Gregory YH Lip**  
Consultant: Bayer, Astellas, Merck, Sanofi, BMS/Pfizer, Daiichi Sankyo, Biotronik, Portola, Boehringer Ingelheim. Speakers bureau: Bayer, BMS/Pfizer, Boehringer Ingelheim, Sanofi-Aventis

**Trudie Lobban MBE**  
None

**Professor Lorenzo Mantovani**  
Research grants: Bayer Research, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb. Consultant/Advisory Board member: Bayer

**Dr Ayrton Massaro**  
None

**Rod Mitchell**  
None disclosed

**Professor Bo Norrving**  
Advisor/consultant: PhotoThera, SERVIER, SYGNIS Pharma AG. Speaker/member of a speakers bureau: Allergan, Bayer HealthCare Pharmaceuticals. Boehringer Ingelheim Pharmaceuticals

**Dr David KL Quek**  
None

**Dr Walter Reyes-Caorsi**  
Advisory Board member: Bayer Uruguay S.A. Speaker: Bayer Uruguay

**Professor Dr Kui-Hian Sim**  
Ongoing clinical trial and Investigator fees: Sanofi, Roche, Eli Lily

**Professor Norio Tanahashi**  
None

**Professor Hung-Fat Tse**  
Advisor/consultant: Bayer Schering Pharma, Boehringer Ingelheim Pharmaceuticals, Sanofi-Aventis, St. Jude Medical, Cordis Corporation, Medtronic, GlaxoSmithKline, Merck Sharp & Dohme Corp

**Professor Panos Vardas**  
Consultant/honoraria: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Medtronic, Menarini, Servier

**Dr Xavier Viñolas**  
Consultant: Bayer, Medtronic, St. Jude Medical, Boston Scientific

**Professor Byung-Woo Yoon**  
None

**Professor Shu Zhang**  
None disclosed